

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number	:	10/560,378	Confirmation No.:	9632
Applicant	:	Toshiyuki HORI		
Filed	:	January 22, 2007		
Title	:	PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING TH1-MEDIATED IMMUNE DISEASES		
TC/Art Unit	:	1649		
Examiner:	:	Robert Clinton HAYES		
Docket No.	:	58777.000018		
Customer No.	:	21967		

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, Applicants submit attached Form PTO/SB/08B (modified) for consideration and request the references cited therein be made of record by the U.S. Patent and Trademark Office in the above-captioned application.

Applicants respectfully point out that the submission of the listed references in this Information Disclosure Statement is not an admission that they are prior art or that they are material to patentability of any claims of the application. Also, the submission of this Information Disclosure Statement is not an indication that a search has been made by Applicants.

The references listed in the attached Form PTO/SB/08B were cited in the Supplementary European Search Report dated June 2, 2009, for corresponding International Application No. PCT/JP2004/008205, a copy of which is enclosed.

In considering the cited references enclosed with this communication, it may be noted by the Examiner that certain of the references may contain markings, underlinings, and/or other notations. These markings, underlinings, and/or other notations are not to be construed as drawing the Examiner's attention either to selected parts or away from other parts of the cited references. Any such markings were either present on the copies of the cited references obtained by

the associated individuals, or were made thereon during the study of the references by the associated individuals.

Consideration of the foregoing plus the prompt return of a copy of the enclosed Form PTO/SB/08B (modified) with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.


In accordance with 37 C.F.R. § 1.97(b)(3), this Information Disclosure Statement is being filed before the mailing date of any of a first Office Action on the merits. Accordingly, no fee is due. However, in the event the USPTO determines that a fee is due to enter and consider this Information Disclosure Statement, the USPTO is authorized to charge such fee to the undersigned's **Deposit Account No. 50-0206.**

Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated: July 24, 2009

By:



Alexander H. Spiegler
Registration No. 56,625

Hunton & Williams LLP
Intellectual Property Department
1900 K Street, N.W.
Suite 1200
Washington, DC 20006
(202) 955-1500 (telephone)
(202) 778-2201 (facsimile)
AHS/mec